Company intelligence / Profile preview

Samsara Therapeutics

Oxford, Oxfordshire, United Kingdomsamsaratherapeutics.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Samsara Therapeutics develops small molecule drugs that activate autophagy to treat age-related neurodegenerative diseases. Their most advanced programs are in preclinical development targeting ALS, CMT Type Ia, and Parkinson's disease. The company uses a proprietary phenotypic screening platform based on patient-derived iPSCs to discover novel compounds that restore or enhance cellular autophagy. No clinical results have been reported yet as all lead candidates remain preclinical.

Therapeutic areas: Neurology
Modalities: Small moleculesEnzymes
Industry: Biotech

Drug pipeline

5 assets

SAM001

Preclinical

4 more assets in the full pipeline.

Partnerships

Apollo Health Ventures led Series A funding roundadditional support from patient advocacy organizations.

Beyond the preview

Go deeper on Samsara Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samsara Therapeutics.